At PM Life Sciences Consulting, clinical development is about more than just regulatory approval. It’s about building programs that lead to real-world use, reimbursement, and system adoption. From day one, we align clinical strategy with market access to ensure that new therapies are not only approved, but adopted and funded.

We embed payer, HTA, and health system needs into trial design and development strategy. That means shaping protocols that generate the right evidence - whether that’s quality of life improvements, health resource impact, or cost-effectiveness. Our expertise covers every stage, from early development to final study readouts, ensuring trials support compelling value stories for both regulators and payers.

Our services include:

• Clinical development strategy integrated with access and reimbursement thinking

• Trial design consultation to capture endpoints that matter to HTA bodies and healthcare systems

• Interim leadership (Medical Director, CMO, UK GM) for seamless cross-functional oversight

• Real-world evidence planning - including observational studies and pragmatic trial extensions

• Health technology assessment (HTA) support, including dossier preparation and mock panels

• Launch readiness, medical communication, and market access training for cross-functional teams

We don’t work in silos. Our team bridges clinical development, medical affairs, and market access to deliver cohesive, efficient programs that translate scientific innovation into system-level adoption.

The result? Clinical development that’s credible, investable, and designed for real-world impact—not just regulatory success.